Trials / Completed
CompletedNCT02965664
Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects
A Phase 2a, Double-Masked, Randomized, Placebo-Controlled, Single-Administration Study to Establish Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Orasis Pharmaceuticals Ltd. · Industry
- Sex
- All
- Age
- 40 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A study to Establish Safety, Tolerability, and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PresbiDrops (CSF-1) | PresbiDrops (CSF-1) is a topical ophthalmic drug. |
| DRUG | Placebo | Placebo drops contain the same ingredients as PresbiDrops except for the active ingredients |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2017-04-01
- Completion
- 2017-04-01
- First posted
- 2016-11-17
- Last updated
- 2017-08-01
Locations
2 sites across 1 country: Israel
Source: ClinicalTrials.gov record NCT02965664. Inclusion in this directory is not an endorsement.